Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

NOXOPHARM LIMITED

ABN

84 608 966 123

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

Class of +securities issued or to be issued	(a) Fully Paid Ordinary Shares (NOX)	
	beissued	(b) Unlisted Option Expiry, 28/02/21, Exercisable@ \$0.30 (NOXAD)
2	Number of +securities issued or	(a) 685,000 Fully Paid Ordinary Shares (NOX)
	to be issued (if known) or maximum number which may be issued	(b) (685,000) Unlisted Option Expiry, 28/02/21, Exercisable @ \$0.30 (NOXAD).
3	Principal terms of the +securities	(a) Fully Paid Ordinary Shares (NOX)
	(e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for	 (b) Unlisted Option Expiry, 28/02/21, Exercisable @ \$0.30 (NOXAD)
	payment; if +convertible securities, the conversion price and dates for conversion)	

⁺ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	(a) Yes (b) N/A
	 If the additional *securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or 	
	interest payment	
5	Issue price or consideration	 (a) \$0.30 cents per share, raising a total of \$205,500 on exercise (b) N/A
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Conversion of 685,000 unlisted options which are a part of the 3,277,858 Restricted Options issued under Prospectus and released on 1 April 2017. Exercise Price \$0.30 per ordinary share. Expiry on 28 February 2021.
6a	Is the entity an ⁺ eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	27 November 2017
6с	Number of +securities issued without security holder approval under rule 7.1	Nil
6d	Number of ⁺ securities issued with security holder approval under rule 7.1A	Nil

бе	Number of ⁺ securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of +securities issued under an exception in rule 7.2	685,000 Fully Pa Rule 7.2 Exceptio	aid Ordinary Shares – ASX Listing on 4
6g	If ⁺ securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the ⁺ issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	See Annexure 1	
7	+Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	25 January 2018 Number	+Class
8	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in section 2 if applicable)	61,627,254 + 685,000 62,312,254	Fully Paid Ordinary Shares (NOX)

⁺ See chapter 19 for defined terms.

		Number	+Class
9	Number and ⁺ class of all ⁺ securities not quoted on ASX (<i>including</i> the ⁺ securities in section 2 if applicable)	46,885,465	Fully Paid Ordinary Shares (NOXAE) Escrow to 09/08/2018
		2,277,858 (685,000) 1,592,858	Unlisted Option Expiry 28/02/21, Exercisable @ \$0.30 (NOXAD)
		1,092,000	
		18,950,358	Unlisted Option Expiry 28/02/21, Exercisable @ \$0.30 (NOXAF) Escrow to 09/08/2018
		500,000	Unlisted Option, Expiry 27/11/2020, Exercisable @ \$1.0158 (NOXAT)
		500,000	Unlisted Option, Expiry 27/11/2020, Exercisable @ \$1.2189 (NOXAT)
		263,158	Unlisted Option Expiry, 30/11/2021, Exercisable @ \$1.08, vest if employed at 1 December 2018 (NOXAT)
		263,158	Unlisted Option Expiry, 30/11/2021, Exercisable @ \$1.08, vest if employed at 1 December 2019 (NOXAT)
		263,154	Unlisted Option Expiry, 30/11/2021, Exercisable @ \$1.08, vest if employed at 1 December 2020 (NOXAT)
		3,000,000	Unlisted Option Expiry, 18 January 2020, Exercisable @ \$0.80. Unable to be exercised prior to 18 July 2018 (NOXAT)
		4,789,470	Total (NOXAT)
10	Dividend policy (in the case of a	The Compar	ny currently does not have a dividend
	trust, distribution policy) on the increased capital (interests)	Policy	,,,

Part 2 - Pro rata issue


increased capital (interests)

- 11 Is security holder approval required?
- 12 Is the issue renounceable or nonrenounceable?

- ¹⁴ ⁺Class of ⁺securities to which the offer relates
- 15 +Record date to determine entitlements
- 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
- 17 Policy for deciding entitlements in relation to fractions
- 18 Names of countries in which the entity has security holders who will not be sent new offer documents

Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.

- 19 Closing date for receipt of acceptances or renunciations
- 20 Names of any underwriters
- 21 Amount of any underwriting fee or commission
- 22 Names of any brokers to the issue
- 23 Fee or commission payable to the broker to the issue
- 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders
- 25 If the issue is contingent on security holders' approval, the date of the meeting



ontingent on approval, the

⁺ See chapter 19 for defined terms.

26	Date entitlement and acceptance
	form and offer documents will be
	sent to persons entitled

- 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
- 28 Date rights trading will begin (if applicable)
- 29 Date rights trading will end (if applicable)
- 30 How do security holders sell their entitlements *in full* through a broker?
- 31 How do security holders sell *part* of their entitlements through a broker and accept for the balance?
- 32 How do security holders dispose of their entitlements (except by sale through a broker)?
- 33 ⁺Issue date

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of +securities (*tick one*)


(b)

- (a) +Securities described in Part 1
 - All other ⁺securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities



Tick to	indicate	you	are	providing	the	information	or
docume	ents						

35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional ⁺ securities
Entities	s that have ticked box 34(b)
38	Number of ⁺ securities for which ⁺ quotation is sought
39	⁺ Class of ⁺ securities for which quotation is sought
40	Do the ⁺ securities rank equally in all respects from the ⁺ issue date with an existing ⁺ class of quoted ⁺ securities?
	 If the additional *securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of
	another ⁺ security, clearly identify that other ⁺ security)

⁺ See chapter 19 for defined terms.

	Number	+Class
42 Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in clause 38)		

Quotation agreement

- ¹ ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Print name:

(Company Secretary) David Franks

Date: 25 January 2018

== == == == ==

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital			
Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
nsert number of fully paid ⁺ ordinary ecurities on issue 12 months before the issue date or date of agreement to issue	85,171,429		
 securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period <i>Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items</i> 	18,709,167		
2 month period	103,880,596		
ordinary securities cancelled during that 2 month period	-		

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"				
"B"	0.15 [Note: this value cannot be changed]			
<i>Multiply</i> "A" by 0.15	15,582,089			
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used				
 <i>Insert</i> number of ⁺equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued: Under an exception in rule 7.2 	8,317,123			
Under rule 7.1A				
 With security holder approval under rule 7.1 or rule 7.4 				
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 				
"C"	8,317,123			
Step 4: Subtract "C" from ["A" x " placement capacity under rule 7.1				
"A" x 0.15	15,582,089			
Note: number must be same as shown in Step 2				
Subtract "C"	8,317,123			
Note: number must be same as shown in Step 3				
<i>Total</i> ["A" x 0.15] – "C"	7,264,966 [Note: this is the remaining placement capacity under rule 7.1]			

Part 2

Rule 7.1A – Additional placem	ent capacity for eligible entities		
Step 1: Calculate "A", the base fig capacity is calculated	jure from which the placement		
" A " Note: number must be same as shown in	103,880,596		
Step 1 of Part 1			
Step 2: Calculate 10% of "A"			
"D"	0.10		
	Note: this value cannot be changed		
Multiply "A" by 0.10 10,388,059			
7.1A that has already been used Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil		
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 			

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining
placement capacity under rule 7.1A

"A" x 0.10 Note: number must be same as shown in Step 2	10,388,059
<i>Subtract</i> "E" <i>Note: number must be same as shown in</i> <i>Step 3</i>	Nil
<i>Total</i> ["A" x 0.10] – "E"	10,388,059 Note: this is the remaining placement capacity under rule 7.1A